American College of Gastroenterology guideline on the management of Helicobacter pylori infection (Q34645482)

3 August 2017

American College of Gastroenterology guideline on the management of Helicobacter pylori infection (English)

1 reference

Helicobacter pylori infectious disease

3 August 2017

0 references

1 reference

1 reference

William D Chey

1

1 reference

3 August 2017

Benjamin C Y Wong

series ordinal

2

1 reference

3 August 2017

Practice Parameters Committee of the American College of Gastroenterology

series ordinal

3

1 reference

3 August 2017

language of work or name

English

0 references

publication date

29 June 2007

1 reference

The American Journal of Gastroenterology

3 August 2017

1 reference

3 August 2017

102

1 reference

3 August 2017

1808-1825

1 reference

3 August 2017

8

1 reference

Recent developments in the epidemiology of Helicobacter pylori

3 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Helicobacter pylori-related disease: guidelines for testing and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Helicobacter pylori eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer: a 5-year prospective, randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Helicobacter pylori and MALT lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Treatment of gastric mucosa-associated lymphoid tissue lymphoma: Helicobacter pylori eradication and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Long-term clinical outcome of Helicobacter pylori eradication for gastric mucosa-associated lymphoid tissue lymphoma with a reference to second-line treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Guidelines for the management of dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Does Helicobacter pylori eradication affect symptoms in nonulcer dyspepsia: a 5-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Risk factors for ulcer development in patients with non-ulcer dyspepsia: a prospective two year follow up study of 209 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Systematic review: the effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Symptom response and healing of erosive esophagitis with proton-pump inhibitors in patients with Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

There is no difference in the disease severity of gastro-oesophageal reflux disease between patients infected and not infected with Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Should we eradicate Helicobacter pylori in non-steroidal anti-inflammatory drug users?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Should we eradicate Helicobacter pylori before prescribing an NSAID? Result of a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

MELD vs Child-Pugh and creatinine-modified Child-Pugh score for predicting survival in patients with decompensated cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Iron-deficiency anemia and Helicobacter pylori infection: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Endemic iron deficiency associated with Helicobacter pylori infection among school-aged children in Alaska

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Iron deficiency and Helicobacter pylori infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

A controlled, household-randomized, open-label trial of the effect that treatment of Helicobacter pylori infection has on iron deficiency in children in rural Alaska.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Helicobacter pylori eradication and gastric preneoplastic conditions: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Long term follow up of patients treated for Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Accurate diagnosis of Helicobacter pylori. Urease tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Prospective comparison of commercially available rapid urease tests for the diagnosis of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

The effect of GI bleeding on Helicobacter pylori diagnostic testing: a prospective study at the time of bleeding and 1 month later

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Accurate diagnosis of Helicobacter pylori with biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Accurate diagnosis of Helicobacter pylori. Culture, including transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Increased rate of Helicobacter pylori infection detected by PCR in biopsies with chronic gastritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Real-time PCR detection and frequency of 16S rDNA mutations associated with resistance and reduced susceptibility to tetracycline in Helicobacter pylori from England and Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Development of a highly sensitive method for detection of clarithromycin-resistant Helicobacter pylori from human feces

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Primary clarithromycin resistance in Italy assessed on Helicobacter pylori DNA sequences by TaqMan real-time polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Accurate diagnosis of Helicobacter pylori. Polymerase chain reaction tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Accurate diagnosis of Helicobacter pylori. Serologic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Enzyme-linked immunosorbent assay for Helicobacter pylori needs adjustment for the population investigated

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection -- a critical review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Accurate diagnosis of Helicobacter pylori. 14C-urea breath test

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Helicobacter pylori antigen stool test and 13C-urea breath test in patients after eradication treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Evaluation of the Ez-HBT Helicobacter blood test to establish Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Negative effect of ranitidine on the results of urea breath test for the diagnosis of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

False negative urea breath tests with H2-receptor antagonists: interactions between Helicobacter pylori density and pH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Accuracy of breath tests using low doses of 13C-urea to diagnose Helicobacter pylori infection: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Stool antigen test for the diagnosis of Helicobacter pylori infection: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

The stool antigen test for detection of Helicobacter pylori after eradication therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Evaluation of the Helicobacter pylori stool antigen test for monitoring eradication therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Accuracy of the stool antigen test in the diagnosis of Helicobacter pylori infection before treatment and in patients on omeprazole therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Lack of accuracy of the noninvasive Helicobacter pylori stool antigen test in patients with gastroduodenal ulcer bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

A negative rapid urease test is unreliable for exclusion of Helicobacter pylori infection during acute phase of ulcer bleeding. A prospective case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Usefulness of a delayed test for the diagnosis of Helicobacter pylori infection in bleeding peptic ulcer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Noninvasive Helicobacter pylori testing for the "test-and-treat" strategy: a decision analysis to assess the effect of past infection on test choice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Endoscopic biopsy requirements for post-treatment diagnosis of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta‐analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Seven-day therapy for Helicobacter pylori in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Recent use of proton pump inhibitor-based triple therapies for the eradication of H pylori: a broad data review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Meta-analysis: the influence of pre-treatment with a proton pump inhibitor on Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Is it time for quadruple therapy to be first line?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

High eradication rates of Helicobacter pylori with a new sequential treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Clarithromycin-resistant genotypes and eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Review article: the treatment of refractory Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

How to treat Helicobacter pylori. First-line, second-line, and future therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Systematic review and meta-analysis: importance of CagA status for successful eradication of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Severe neutropenia among healthy volunteers given rifabutin in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Rifabutin-associated hypopyon uveitis in human immunodeficiency virus-negative immunocompetent individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Furazolidone combination therapies for Helicobacter pylori infection in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Pharmacological, therapeutic and toxicological properties of furazolidone: some recent research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Third-line rescue therapy with levofloxacin after two H. pylori treatment failures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for patient management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Effects of acid suppression and bismuth medications on the performance of diagnostic tests for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01393.X

Meta-analysis: the relationship between Helicobacter pylori infection and gastro-oesophageal reflux disease

21 January 2018

1 reference

12 January 2024

https://opencitations.net/index/api/v1/citations/10.1046/J.1365-2036.2003.01665.X

Identifiers

DOI

10.1111/J.1572-0241.2007.01393.X

1 reference

3 August 2017

1 reference